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Background: Clinical resistance to chemotherapeutic agents is one of the major hindrances in the treatment of
human cancers. Erythroblastosis virus E26 oncogene homolog 1 (ETS1) is involved in the drug resistance of various
cancer cells, and is overexpressed in drug-resistant human breast cancer cell lines. In this study, we investigated the
effects of ETS1 on adriamycin resistance in MCF-7/ADR cells.
Methods: siRNAs against ETS1 or negative control siRNAs was transfected to MCF-7/ADR breast cancer cells. Reverse
transcription-PCR and Western blotting were used to determine the mRNA and protein expression of ETS1 and MDR1.
The cytotoxicity of adriamycin was assessed using the MTT assay. Drug efflux was investigated by flow cytometry using
the Rhodamine 123 intracellular accumulation assay.
Results: ETS1 mRNA and protein was significantly overexpressed in MCF-7/ADR cells, compared to MCF-7 cells. ETS1
siRNA successfully silenced ETS1 mRNA and protein expression. Silencing of ETS1 also significantly reduced the mRNA
and protein expression levels of MDR1 (multidrug resistance 1; also known as ABCB1, P-glycoprotein/P-gp), which is a
major ATP-binding cassette (ABC) transporter linked to multi-drug resistance in cancer cells. Silencing of ETS1
significantly increased the sensitivity of MCF-7/ADR cells to adriamycin, compared to cells transfected with negative
control siRNA. In addition, intracellular accumulation of Rhodamine 123 significantly increased in MCF-7/ADR cells
transfected with ETS1 siRNA, indicating that silencing of ETS1 may reduce drug efflux.
Conclusions: This study demonstrates that drug resistance can be effectively reversed in adriamycin-resistant breast
carcinoma cells through delivery of siRNAs targeting ETS1.
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Breast cancer is a systemic disease, with the primary
tumor representing the localized form of the disease.
Therefore, systemic adjuvant therapies play an important
role in the treatment of breast cancer, and adjuvant
chemotherapy is a central component of systemic adju-
vant therapy for breast cancer. However, the resistance
of tumor cells to multiple chemotherapeutic agents is a
major obstacle to the success of cancer chemotherapy,
and has been strongly associated with treatment failure* Correspondence: xs52308@hotmail.com; dongx@upmc.edu
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reproduction in any medium, provided the or[1]. Multidrug resistance (MDR) refers to the resistance
of tumors to not only a single cytotoxic drug, but cross-
resistance to a wide range of drugs with unrelated func-
tion and structure [2].
The mechanisms of drug resistance are complicated,
and include decreased intracellular drug accumula-
tion, which can occur due to increased drug efflux by
the ATP-binding cassette (ABC) transporters such as
multidrug resistance 1 (MDR1; also known as ABCB1,
P-glycoprotein/P-gp). A number of important antican-
cer agents derived from natural products, such as vin-
caalkaloids, anthracyclines (daunorubicin, adriamycin)
and taxanes are substrates of MDR1. Other mecha-
nisms of drug resistance include decreased conversion
of a drug to its active form, altered expression of the
target enzyme or receptor, decreased affinity of the tar-
get enzyme or receptor for the drug, enhanced repair of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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survival genes [3].
Reversal of MDR has been the focus of medical studies
for many years. Previous research reported that down-
regulation of the ABC family members or altering the
expression of apoptosis/survival genes can reverse MDR
in cancer cells [4,5]. In the past two decades, there has
been a worldwide effort to investigate a large number of
diverse chemical agents for their ability to overcome
MDR. Although these chemical agents are effective in
cell culture and animal models, they usually fail in the
clinical setting. The reasons for this high rate of failure
include the necessity of extremely high inhibitor concen-
trations which induce unwanted side effects, and unpre-
dictable pharmacokinetic interactions with therapeutic
anticancer agents [6].
RNA interference (RNAi) technology provides a novel
therapeutic approach for the treatment of drug-resistant
tumors. Various RNAi strategies have been applied to
reverse MDR in different tumor models in vitro and
in vivo by down-regulating genes associated with
MDR, such as multidrug resistance 1(MDR1), multidrug
resistance-associated protein(MRP) and breast cancer re-
sistance protein (BCRP) [7-9]. Recently, it was reported
that Erythroblastosis virus E26 oncogene homolog 1
(ETS1) gene is over-expressed in drug-resistant human
breast cancer cell lines [10]. Experimental studies have
shown that ETS1 is involved in the drug resistance
of ovarian and pancreatic cancer cells [11,12]. Based
on these observations, we hypothesized that down-
regulation of ETS1 using siRNAs would result in height-
ened drug sensitivity and reverse MDR in breast cancer
cells. In this study we investigated the effects of ETS1 on
adriamycin resistance in MCF-7/ADR cells, which are
typical multidrug-resistant human breast cancer cells that
were selected by exposure to adriamycin [13].
Materials and methods
Cell lines and culture
Human MCF-7 and MCF-7/ADR breast cancer cell
lines were obtained from XiangYa Central Experi-
ment Laboratory (Changsha, China), and maintained in
RPMI1640 medium (GIBCO, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS), peni-
cillin, and streptomycin at 37°C in 5% CO2 as described
by us previously [14].
Synthesis of siRNAs
A double-stranded siRNA oligo nucleotide targeting
ETS1 (sense, 5′-ACUUGCUACCAUCCCGUAC-dTT-3′;
antisense, 5′-GUACGGGAUGGUAGCAAGU-dTT-3′)
was designed based on Ito et al. [15] and synthesized
by Shanghai Genepharma Co. Ltd. (China). A pair of
negative control siRNAs were also designed by varyingthe sequence of siRNA-ETS1; the negative control
siRNAs were not homologous to any known sequences
in GenBank (sense, 5′-UUCUCCGAACGUGUCACG
UTT-3′; antisense, 5′-ACGUGACACGUUCGGAGA
ATT-3′). The siRNAs were dissolved in siRNA dilution
buffer (Shanghai Genepharma Co. Ltd. China) to a final
concentration of 20 μmol/L.
RT-PCR analysis
Total cellular RNA was isolated using TRIzol (Invitrogen)
according to the manufacturer’s instructions. For reverse
transcription (RT)-PCR, 5 μg of total RNA per sample was
reverse transcribed using the Reverse Transcription Reac-
tion Kit (Fermentas, St. Leon-Rot, Germany) according to
the manufacturer’s instructions. The cDNA (1 μl) was
amplified by PCR (pre-denaturation step at 95°C for 5 min;
followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and






GGTGGACGAT-3′. The reaction products were visualized
by electrophoresis on 1.5% agarose gels using 1xTBE buffer
containing 0.5 μg/ml ethidium bromide. The final, normal-
ized results were calculated by dividing the relative tran-
script levels of the target genes by the relative transcript
levels of GAPDH.
Western blotting
Western blotting was performed as described in our previ-
ous study [14]. Briefly, cells were harvested and rinsed with
PBS. Cell extracts were prepared using lysis buffer (contain-
ing 8 M urea, 10% SDS, 1 M DTT and protease inhibitors)
and centrifuged at 12,000 g at 4°C. Total protein concentra-
tion was measured using the BCA assay. Cellular extracts
containing 30 μg total protein were electrophoresed on 10%
SDS-PAGE gels and then transferred onto polyvinylidene
difluoride membranes (Invitrogen). The membranes were
incubated for 2 h in blocking solution containing 5%
non-fat dry milk to inhibit non-specific binding, then
incubated with primary anti-ETS-1 (1:2000; Epitomics Inc.,
Burlingham, CA, USA) and anti-β-actin FLAG (1:5000;
Abcam, Cambridge, MA, USA) antibodies for 2 h. After
several washes in PBS, the membranes were incubated with
HRP-conjugated secondary antibodies (1:3000; Abcam,
Cambridge, United Kingdom). The blots were developed
using an ECL chemiluminescent kit (Beyotime, Haimen,
China), and exposed to X-ray film for 30 s to 2 min.
Transfection of siRNAs
MCF-7/ADR cells (3 × 105) were plated into the 35 mm
wells of 6-well plates and allowed to adhere for 24 h.
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fection reagent (Invitrogen, Carlsbad, CA, USA) and 5 μl
of siRNA solution was added to Buffer EC-R (Qiagen,
Hilden, Germany), to prepare a total volume of 500 μl
per well. The complex was gently mixed, incubated
at room temperature for 20 min, and added to the
wells containing 2 ml DMEM without 10% FBS, after
4-6 h, then the cells were incubated using normal
cell culture conditions. Untransfected control and negative
control cells (negative control siRNA) were prepared in
parallel.
Cytotoxicity assay
Cell proliferation was determined using the MTT assay.
Cells were seeded at 1×104/well in 96-well microtiter
plates. After 24 h incubation, the cells were trans-
fected with siRNAs, incubated for 5 h, and then treated
with different concentrations of adriamycin (Huasu
Pharmaceuticals Inc, Beijing, China) for 48 h. Then,
20 μl of 5 mg/ml MTT solution was added, incubated for
4 h at 37˚C, the medium and MTT solution were dis-
carded, DMSO (150 μl) was added to each well, and the
plates were shaken for 30 min. The optical density (OD)
values were read using a Synergy HT multi-detection mi-
croplate reader (Bio-Tek Instruments, Inc., Winooski,
VT, USA) at λ = 570 nm. Relative drug resistance was de-
termined by comparing the IC50 values (drug concentra-
tion causing a 50% inhibition of cell growth, determined
from the growth inhibition curves) for each group.
Intracellular Rhodamine 123 accumulation assay
The fluorescence intensity of intracellular Rhodamine
(Rh123) accumulation was determined by flow cytome-
try according to standard procedures [3,16]. Cells were
plated at 2×105/well in 6-well plates, incubated for 24 h,
transiently transfected with siRNAs and then incubated
for 48 h. Subsequently, Rh123 was added at a final con-
centration of 10 μg/ml, the cells were incubated for 1 h,
harvested, washed twice with cold PBS, and then placed
in iced-water until analysis. After half an hour, the fluor-
escence intensity of the cells was determined using the
FACS Calibur™ flow cytometer (Becton Dickinson, San
Jose, CA. USA) at an excitation wavelength of 488 nm
and a receiving wavelength of 575 nm.
Statistical analysis
All RT-PCR and Western blotting data were normalized
to GAPDH or β-actin, respectively. Statistical analysis
was performed using SPSS 13.0 (SPSS, Chicago, IL,
USA). All data are presented as the mean ± standard de-
viation and one-way ANOVA and Dunnett’s T3 post test
was used to determine the statistical significance. Differ-
ences between groups were analyzed using two-sided
t-tests. P <0.05 was considered statistically significant.Results
ETS1 is up-regulated in MCF-7/ADR cells compared to
MCF-7 cells
Initially, we determined the mRNA and protein expres-
sion of MDR1 in the MCF-7 and MCF-7/ADR cells to
confirm the Adriamycin-resistance. The levels of mRNA
and protein of MDR1 were highly increased in the
MCF-7/ADR cells as compared with the MCF-7 cells
(Figure 1A,B,E and F). The expression of ETS1 mRNA
in MCF-7 and MCF-7/ADR cells was determined by RT-
PCR. The size of the PCR products for ETS1 and
GAPDH were 345 bp and 225 bp, respectively. As shown
in Figure 1, the expression of ETS1 mRNA in MCF-7/
ADR cells was 4.1-fold higher than the levels in parental
MCF-7 cells (P < 0.05). Next, we tested whether the
ETS1 protein is up-regulated in MCF-7/ADR cells. As
shown in Figure 1C and D, the level of ETS1 in MCF-7/
ADR cells was significantly higher than that of MCF-7
cells. These observations clearly indicated that ETS1 is
over-expressed in MCF-7/ADR cells (Figure 1).
Confirmation of ETS1 silencing in ETS1 siRNA-transfected
MCF-7/ADR cells
To confirm the RNAi-mediated silencing of ETS1 in
MCF-7/ADR cells, ETS1 mRNA and protein expression
were quantified by RT-PCR and Western Blotting re-
spectively, 48 h after transfection of ETS1 siRNA. As
shown in Figure 2A, the PCR products for ETS1 and
GAPDH were 345 bp and 225 bp respectively. As shown
in Figure 2B, the expression of ETS1 mRNA declined to
60.1% in the siRNA transfected cells, compared to the
negative control cells (P < 0.05); there were no significant
differences between the untransfected control and nega-
tive control transfected cells. Western blot analysis con-
firmed the results of the RT-PCR analysis (Figure 2C).
As shown Figure 2D, ETS1 protein expression was re-
duced by more than 85% in the siRNA-transfected
MCF-7/ADR cells, compared to the negative control
transfected cells; there was no significant difference be-
tween the untransfected cotrol cells and negative control
transfected MCF-7/ADR cells.
Silencing of ETS1 down-regulated MDR1 mRNA and
protein expression in MCF-7/ADR cells
Next, we investigated whether silencing of ETS1 can
reduced the expression of MDR1 mRNA and protein
in MCF-7/ADR cells. To answer the question, we deter-
mined the levels of MDR1 mRNA and protein in the
control and transfected MCF-7/ADR cells. The expres-
sion of MDR1 mRNA was determined in MCF-7/ADR
cells by RT-PCR 48 h after transfection of ETS1 siRNA.
The PCR products for MDR1 and GAPDH were 457 bp
and 225 bp, respectively. As shown Figure 2B, siRNA-
mediated silencing of ETS1 reduced the expression of
Figure 1 The levels of mRNA and protein expression of ETS1 and MDR1 in MCF-7 and MCF-7/ADR cells. (A) RT-PCR analysis and
(B) quantification of ETS1 and MDR1 mRNA expression in MCF-7 and MCF-7/ADR cells (MCF-7/ADR), the mRNA levels were normalized to the
loading control GAPDH. The ratio of ETS1 and MDR1 to GAPDH mRNA was calculated for each group. Data are mean ± SD of three independent
experiments; *P < 0.05 compared with MCF-7 cells. Immunoblotting analysis (C and E) and quantification (D and F) of ETS1 (C and D) and MDR1
(E and F) protein expression MCF-7 and MCF-7/ADR cells. The blots were stripped and reprobed with anti-β-actin antibody to ensure equal protein
loading. The ratio of ETS1 to β-actin protein was calculated for each group. Values are mean ± SD of three independent experiments; *P < 0.05
compared with MCF-7 cells.
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untransfected control MCF-7/ADR cells (P < 0.05); there
was no significant difference between the untrans-
fected control cells and negative control transfected
MCF-7/ADR cells. More importantly, the ETS1 siRNA-
transfected MCF-7/ADR cells resulted in a remarkably
decrease of the protein levels of compared to that in
control and NC siRNA-transfected MCF-7/ADR cells
(Figure 2E and F). For example, the MDR1 level in ETS
siRNA-transfected MCF-7/ADR cells was decreased by
about 50 %, as compared to the levels in the control group
(Figure 2E and F). These observations clearly indicated
that silencing of ETS1 resulted in the down-regulationof MDR1 signaling in human breast cancer MCF-7/
ADR cells.
Silencing of ETS1 restored the chemosensitivity of
MCF-7/ADR cells
Then, we determined the effect of silencing of ETS1 on
the chemosensitivity of MCF-7/ADR cells by Adriamy-
cin. The IC50 for adriamycin in MCF-7/ADR cells was
81.37 ± 6.34 μmol/L at 48 h. As shown Table 1 and
Figure 3, transfection of ETS1 siRNA significantly de-
creased the IC50 for adriamycin in MCF-7/ADR cells, com-
pared to untransfected control cells (P < 0.05); there was
no significant difference between untransfected control
Figure 2 Silencing of ETS1 reduces the mRNA and protein expression of ETS1 and MDR1 in MCF-7/ADR cells. (A) RT-PCR analysis and
(B) quantification of ETS1 and MDR1 mRNA expression in: ETS1 siRNA-transfected cells (ETS1 siRNA); control untransfected cells (Control); and
negative control siRNA transfected cells (NC siRNA) at 48 h after transfection. GAPDH was analyzed in parallel as a loading control; the ratio of
ETS1 to GAPDH mRNA was calculated for each group. Western blot analysis (C and E) and quantification (D and F) of ETS1 (C and D) and MDR1
(E and F) protein expression in: ETS1 siRNA-transfected cells (ETS1 siRNA); control untransfected cells (Control); and negative control
siRNA transfected cells (NC siRNA) at 48 h after transfection, β-actin was analyzed in parallel as a loading control; the ratio of ETS1and
MDR1 to β-actin protein was calculated for each group. Values are mean ± SD of three independent experiments; *P < 0.05 and **P < 0.01 compared
with untransfected control cells.
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These results suggested that MCF-7/ADR cells could be
effectively chemosensitized by siRNA-mediated silencing
of ETS1.
Drug efflux is reduced in ETS1 siRNA -transfected
MCF-7/ADR cells
Adriamycin is transported out of the cell by MDR1 (also
known as ABCB1 and P-gp). As shown Figure 4A,
flow cytometry analysis demonstrated that treatment
of MCF-7/ADR cells with Rh123 significantly in-
creased the number of fluorescent cells, compared tocontrol MCF-7/ADR cells. Moreover, the fluorescence in-
tensity of Rh123, a measure of intracellular Rh123 accumu-
lation, was significantly higher in ETS1 siRNA-transfected
MCF-7/ADR cells (211.26±19.15) than negative control
cells (36.78±3.71; P < 0.01; Figure 4B and Table 2). There
was no significant difference in intracellular Rh123, accu-
mulation in untransfected control cells and negative
control-transfected MCF-7/ADR cells.
Discussion
Chemotherapy is used to treat all stages of breast cancer;
however, MDR severely limits the effects of chemotherapy.
Table 1 IC50 values for adriamycin in MCF-7/ADR cells
Group IC50 (μmol/L) RR
EST1 siRNA 34.63 ± 1.29* 2.35
Negative control siRNA 86.18 ± 5.29 0.94
Control untransfected 81.37 ± 6.34 1.00
Cytotoxicity was assayed as described in methods. IC50 is the drug concentration
(μmol/L) that resulted in a 50% inhibition of cell growth. The RR (relative drug
resistance) of the control cells was set as 1. Results are mean ± SD of triplicate
determinations; *P < 0.05 compared with the controls.
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in drug-resistant human breast cancer cell lines [10]. MCF-
7/ADR cells are typical multidrug-resistant human breast
cancer cells, which were selected by exposure to adriamy-
cin [13]. In this study, we confirmed that ETS1 mRNA and
protein are overexpressed in adriamycin-resistant human
MCF-7/ADR breast cancer cells.
To further investigate the effects of ETS1 on adriamy-
cin resistance in breast cancer, siRNAs targeting ETS1
were transfected into MCF-7/ADR cells. ETS1 siRNAs
significantly suppressed the expression of ETS1 in MCF-
7/ADR cells, and reduced ETS1 mRNA and protein
expression by more than 60% and 85%, respectively,
compared to cells transfected with a negative control
siRNA. Using siRNAs against ETS1, Khanna et al.
demonstrated a reversal in gemcitabine chemosensi-
tivity in gemcitabine-resistant cells [12]. We observed
a similar reversal in adriamycin chemosensitivity using
siRNAs against ETS1 in MCF-7/ADR cells. Silencing of
ETS1 significantly decreased the IC50 value for adriamy-
cin in MCF-7/ADR cells, indicating that silencing of
ETS1 restored the chemosensitivity of MCF-7/ADR cells.Figure 3 Silencing of ETS1 reduces the cytotoxicity of adriamycin
in MCF-7/ADR cells. Cells were untransfected (Control), or transfected
with EST1 siRNA (ETS1 siRNA) or negative control siRNA (NC siRNA), and
then incubated with different concentrations of adriamycin, as indicated
for an additional 48 h. Cell survival was determined using the MTT assay.
Data are mean ± SD of three independent experiments; *P< 0.05
compared with untransfected control cells.MCF-7/ADR cells display an ATP-dependent reduction
in the intracellular accumulation of anthracyclines,
despite the absence of over-expression of MDR1 (also
known as P-glycoprotein/P-gp/ABCB1). A number of
notable, anticancer agents derived from natural products,
such as vinca alkaloids, anthracyclines (daunorubicin,
adriamycin) and taxanes are substrates of MDR1 [6,17,18].
In this study, semi-quantitative RT-PCR analysis indicated
that silencing of ETS1 significantly reduced the expression
of MDR1 mRNA by more than 35% in MCF-7/ADR cells.
The intracellular Rh123 accumulation assay revealed that
drug efflux significantly reduced in MCF-7/ADR cells
transfected with ETS1 siRNA, demonstrating that silencing
of ETS1 downregulated MDR1, which in turn increased
accumulation of adriamycin by reducing the ability of
MDR1/P-glycoprotein to transport the drug out of the cell.
This data is in good agreement with one of the major
mechanisms of drug resistance in cancer cells - decreased
intracellular drug accumulation, which occurs due to in-
creased drug efflux by the ATP-binding cassette (ABC)
transporters such as MDR1/P-glycoprotein [16].
Our findings indicate that ETS1 can regulate the ex-
pression of MDR1 and, in turn, the function of MDR1/
P-glycoprotein. Wilson et al. previously reported that
ETS1 elicited cisplatin resistance via transcriptional acti-
vation of genes whose products have well-described
functions in reducing the toxicity of cisplatin [11]. Taken
together, this evidence indicates that the proto-oncoprotein
ETS1 plays an important role in tumor chemoresistance
via a number of different mechanisms.
In addition to promoting MDR in cancer cells, ETS1 is
also likely to play a role in tumor progression. ETS1 is a
member of the ETS family of transcription factors,
which share a unique DNA binding domain [19]. ETS1
is expressed by a variety of solid tumors, including epi-
thelial carcinomas, sarcomas and astrocytomas. In some
tumor types, expression of ETS1 is either upregulated or
observed exclusively in invasive, higher grade tumors.
High ETS1 levels correlate with poor prognosis in can-
cer of the breast, ovary and cervix [20-22]. Previous
research reported that cells over-expressing MDR1/P-
glycoprotein have increased invasive and metastatic
behavior [23,24]. ETS1 regulates a number of genes
coding for proteases, such as matrix metalloproteinase-1
(MMP1), MMP3 and MMP9, and urokinase type plas-
minogen activator (PLAU). These proteases are known to
be involved in extracellular matrix (ECM) degradation, a
key event required for the invasion of cancer cells [25,26].
It is notable that ETS1 interacts with mutant P53, but
not wild-type P53, which can lead to selective up-
regulation of the MDR1 gene in vitro and in vivo [27]. It
is known that some invasive breast cancer cells express
mutant P53 [28]; the frequency of P53 mutations in
breast cancer is approximately 50% [29]. Our results
Figure 4 Rhodamine 123 (Rh123) efflux assay. (A) MDR1-mediated rhodamine efflux was measured by flow cytometric analysis of Rh123 intracellular
accumulation. Flow cytometry analysis and (B) mean fluorescence intensity of control untransfected MCF-7/ADR cells (Control); control untransfected
MCF-7/ADR cells treated with Rh123(control +Rh123); negative control siRNA transfected MCF-7/ADR cells treated with Rh123(NC siRNA + Rh123); and
ETS1 siRNA-transfected MCF-7/ADR cells treated with Rh123(ETS1 siRNA+ Rh123). Results are mean ± SD of three independent experiments. *P < 0.05
compared with MCF-7/ADR cells treated with Rh123; # P < 0.01 compared with untransfected MCF-7/ADR cells.




Control untransfected + Rh123 36.62±3.68
Negative control siRNA + Rh123 36.78±3.71
ETS1 siRNA + Rh123 211.26±19.15#
*P < 0.05 compared with the MCF-7/ADM cells treated with Rh123; #P < 0.01
compared with the untransfected controls + Rh123.
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sion of MDR1 mRNA less efficiently than the expres-
sion of ETS1 mRNA, whereas close to the frequency of
P53 mutations. This indicates that ETS1 may not be
the only factor which regulates the expression of
MDR1. Further research is required to examine the
mechanisms regulating MDR1 and its down-stream ef-
fectors in ETS1 siRNA transfected cells. This may help
to reveal the mechanisms which regulate MDR1 in cells
without P53 mutations.
Wei et al. Cancer Cell International 2014, 14:22 Page 8 of 8
http://www.cancerci.com/content/14/1/22Abbreviations
EST1: Erythroblastosis virus E26 oncogene homolog 1; siRNAs: small
interfering RNA; MDR1: multidrug resistance 1; P-gp: P-glycoprotein; MTT: 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ABC: ATP-binding
cassette; RNAi: RNA interference; MDR: Multidrug resistance; MRP: Multidrug
resistance-associated protein; BCRP: Breast cancer resistance protein; FBS: Fetal
bovine serum; PBS: Phosphate buffered saline; BCA: Bicinchoninic acid; SDS-
PAGE: Substrate-sodium dodecyl sulfate-polyacrylamide gel electrophoresis;
DMEM: Dulbecco’s modified eagle medium; DTT: Dithiothreitol; HRP: Horseradish
peroxidase; ECL: Enhanced chemiluminescence; cDNA: Complementary
deoxyribonucleic acid; GAPDH: Glyceraldehyde phosphate dehydrogenase gene.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design: JRW, YZ, GQJ, DX. Development of methodology:
JRW, YZ, GQJ, DX. Acquisition of data: JRW, YZ, GQJ. Analysis and interpretation
of data: JRW, YZ, GQJ, DX. Writing and review of the manuscript: JRW, YZ, GQJ,
DX. Study supervions: GQJ, DX. All authors read and approved the final
manuscript.
Author details
1Department of General Surgery, The Second Affiliated of Hospital of
Soochow University, Suzhou, Jiangsu 215004, China. 2Department of General
Surgery, Yancheng City No. 1 People’s Hospital, Yancheng, Jiangsu 224005,
China. 3Department Urology, University of Pittsburgh Cancer Institute,
University of Pittsburgh Medical College, University of Pittsburgh, Shadyside
Medical Center, Suit G37, 5200 Center Avenue, Pittsburgh, PA 15232, USA.
Received: 5 August 2013 Accepted: 29 January 2014
Published: 7 March 2014
References
1. Kerbel RS: A cancer therapy resistant to resistance. Nature 1997,
390:335–336.
2. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of
ATP-dependent transporters. Nat Rew Cancer 2002, 2:48–58.
3. Young AM, Allen CE, Audus KL: Efflux transporters of the human placenta.
Adv Drug Deliv Rev 2003, 55:125–132.
4. Ma Y, Wink M: Lobeline: a piperidine alkaloid from Lobe-lia can reverse
P-gp dependent multi-drug resistance in tumor cells. Phytomedicine 2008,
15(9):754–758.
5. Bhardwaj A: Resveratrol inhibits proliferation, induces apoptosis, and
overcomes chemoresistance through down-regulation of STAT3 and
nuclear factor kappaβ-regulated antiapoptotic and cell survival gene
products in human multiple myeloma cells. Blood 2007, 109:2293–2302.
6. Thomas H, Coley HM: Overcoming multidrug resistance in cancer: an
update on the clinical strategy of inhibiting p-glycoprotein. Cancer
Control 2003, 10:159–165.
7. Hao W, William NH, Yang JM: Small interfering RNA induced suppression
of MDR1 (P-glycoprotein) restores sensitivity to Multi drug resistant
cancer cells. Cancer Res 2003, 63(7):1515.
8. Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, Liu H, Xiao H: In vitro and in
vivo inhibition of MRP gene expression and reversal of multi drug
resistance by siRNA. Basic Clin Pharmacol Toxicol 2011, 108:177–184.
9. Ee PL, He X, Ross DD, Beck WT: Modulation of breast cancer resistance
protein (BCRP/ABCG2) gene expression using RNA interference. Mol
Cancer Ther 2004, 3:1577–1584.
10. Kars MD, Işeri OD, Gündüz U: Drug resistant breast cancer cells over-express
Ets1 gene. Biomed Pharmacother 2010, 10:1016–1021.
11. Wilson LA, Yamamoto H, Singh G: Role of the transcription factor Ets-1 in
cisplatin resistance. Mol Cancer Ther 2004, 3(7):823–832.
12. Khanna A, Mahalingam K, Chakrabarti D, Periyasamy G: Ets-1 expression
and gemcitabine chemoresistance in pancreatic cancer cells. Cell Mol Biol
Lett 2011, 1(16):101–113.
13. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A
multidrug resistance transporter from human MCF-7 breast cancer cells.
Proc Natl Acad Sci U S A 1998, 95(26):15665–15670.
14. Jiang GQ, Xiao M, Zeng Y, Nagabhushanam K, Majee M, Xiao D: Targeting
beta-catenin signaling to induce apoptosis in human breast cancer cellsby z-Guggulsterone and Gugulipid extract of Ayurvedic medicine plant
Commiphora mukul. BMC Complement Altern Med 2013, 13:203. doi:
10.1186/1472-6882-13-203.
15. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE:
Prostaglandin E2 enhances pancreatic cancer invasiveness through an
Ets1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004,
64:7439–7446.
16. Lu Y, Pang TX, Wang JX, Xiong DS, Ma L, Li B, Li QH, Wakabayashi S:
Down-regulation of P-glycoprotein expression by sustained intracellular
acidification in K562/DOX cells. Biochem Biophy Res Comm 2008,
377:441–446.
17. Avendano C, Menendez J: Inhibitors of multidrug resistance to antitumor
agents (MDR). Curr Med Chem 2002, 9:159–193.
18. Coley HM: Overcoming multidrug resistance in cancer: clinical studies of
p-glycoprotein inhibitors. Methods Mol Biol 2010, 596:341–358.
19. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ:
Gain of function mutations in p53. Nat Genet 1993, 4:42–46.
20. Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T: Clinical implications of
expression of Ets1 related to angiogenesis in uterine cervical cancers.
Ann Oncol 2002, 13:1598–1604.
21. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG:
Expression of the transcription factor Ets-1 is an independent prognostic
marker for relapse-free survival in breast cancer. Oncogene 2002,
21:8506–8509.
22. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A,
Ben-Baruch G, Bryne M, Nesland JM: Ets1 messenger RNA expression
is a novel marker of poor survival in ovarian carcinoma. Clin Cancer
Res 2001, 7:551–557.
23. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human
cells by transient exposure to different chemotherapeutic drugs. J Natl
Cancer Inst 1993, 85:632–639.
24. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN: Over-expression of
extracellular matrix metalloproteinase inducer in multidrug resistant
cancer cells. Mol Cancer Res 2003, 1:420–427.
25. Oda N, Abe M, Sato Y: Ets-1 converts endothelial cells to the angiogenic
phenotype by inducing the expression of matrix metallo proteinases
and integrin beta3. Cell Physiol 1999, 178:121–132.
26. Nakada M, Yamashita J, Okada Y, Sato H: Ets1 positively regulates expression
of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic
tumors. J Neuropathol Exp Neurol 1999, 58:329–334.
27. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q,
Zambetti GP, Schuetz JD: Mutant p53 cooperates with Ets and selectively
up-regulates human MDR1 not MRP1. Biol Chem 2001, 276:39359–39367.
28. Zhou W, Muggerud AA, Vu P, Due EU, Sørlie T, Børresen-Dale AL, Wärnberg F,
Langerød A: Full sequencing of TP53 identify identical mutations in situ and
invasive components in breast cancer suggesting clonal evolution. Mol Oncol
2009, 3(3):214–219.
29. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR: Prognostic significance of
mutations to different structural and functional regions of the p53 gene in
breast cancer. Clin Cancer Res 2000, 6(2):443–541.
doi:10.1186/1475-2867-14-22
Cite this article as: Wei et al.: Silencing of ETS1 reverses adriamycin
resistance in MCF-7/ADR cells via downregulation of MDR1. Cancer Cell
International 2014 14:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
